Core Vct I Share Discussion Threads

[yawn3] 27/3/2018 11:52

PSL

being 'dumped' below bid price. Red soon?

[ertugrul] 27/3/2018 08:20

ACP RNS- big one

[webshares] 26/3/2018 13:13

Kibo. PPA imminent

[cpap man] 26/3/2018 09:44

ARS RNS OUT



cf45626 Mar '18 - 09:36 - 12742 of 12747

RNS just out



ifthecapfits26 Mar '18 - 09:36 - 12743 of 12747

Link please as not shown above.

2LB26 Mar '18 - 09:38 - 12744 of 12747

Asiamet Resources Limited ("ARS" or the "Company"), through its Indonesian operating subsidiary PT Kalimantan Surya Kencana ("KSK"), is pleased to report that ahead of moving into the project financing and development phase for its BKM copper project in Central Kalimantan, it has successfully concluded long running negotiations with the Government of Indonesia ("GOI") to amend its existing KSK Contract of Work ("CoW") to secure long term mining tenure.

cf45626 Mar '18 - 09:39 - 12745 of 12747

"Working closely with the GOI to achieve this outcome represents a significant milestone for Asiamet."

"Achieving security of tenure and the fiscal framework for the KSK project significantly enhances our ability to deliver value for all our stakeholders both through the development of the BKM Copper Project and the discovery of further nearby value creating opportunities such as the recent BKZ polymetallic deposit."

adorling26 Mar '18 - 09:40 - 12746 of 12747

That really shows the strength of our relationship with the Indonesian Goverment and Ministry of Mines. 50 years of BKM is great news especially as we suspect we could be joined at the hip with BKZ etc.

Well done Management!

Mr Roper26 Mar '18 - 09:42 - 12747 of 12747

tremendous achievement. Wasn't expecting the CoW amendments to be concluded so quickly. Let's wrap up the feasibility and get the financing sorted asap.

The Asiamet BoD just keep on delivering.

[yawn3] 26/3/2018 07:56

AMP (1.2-1.3)...Good news

London and New York, 26 March 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces a further update regarding its partner company Polarean, Inc, a subsidiary of Polarean Imaging plc ("Polarean").



The Company notes that Polarean Imaging plc has today announced that it is seeking a listing on the AIM Market of the London Stock Exchange ("Admission"). The Company proposes to raise gross proceeds of £3 million by way of a conditional placing through its nominated adviser and broker, Northland Capital Partners Limited (the "Placing") and a conditional subscription (the "Subscription" and together with the Placing, the "Fundraise").



It is expected that Admission will become effective at 8am on or around 29 March 2018 and shares will trade under the AIM symbol 'POLX'. Polarean is expected to have a market capitalisation on admission of at least £11 million.



Amphion has participated in the Placing and following Admission is expected to remain the largest shareholder holding c. 17 million shares, equivalent to 23.2% of the enlarged Share Capital of Polarean.

[cpap man] 23/3/2018 18:37

TSXV:LG



LGC to Focus on Investments in Near-Term Medical Cannabis Production
Canada NewsWire

MONTREAL, March 23, 2018

LGC Capital Ltd.
Symbol: TSX-V: LG

Terminates option with House of Hemp as it no longer meets LGC's investment criteria
MONTREAL, March 23, 2018 /CNW Telbec/ - LGC Capital Ltd. (TSXV: LG) ("LGC") announces that it has formally terminated its option to acquire a 30% interest in South Africa-based House of Hemp (Pty) Ltd, in favour of focusing LGC's resources and cash-strong balance sheet on developing its fast-growing investments in Australia, Montreal/Canada, Jamaica and Europe. LGC also announces that it is examining new near-term cash-flowing investment opportunities in Europe and southern Africa. As previously announced, LGC's 50/50 joint venture with AfriAg (Pty) Ltd had the exclusive right to acquire a 60% interest in House of Hemp.

Logo: LGC Capital Ltd. (CNW Group/LGC Capital Ltd)

The South African Government has not put in place the legislative framework for the legalization of medical cannabis in that country. Although House of Hemp is still actively seeking a full set of commercial licenses, its lack of licenses at present means that it does not meet LGC's strict criteria for near-term production and cash-flow.

As a result, House of Hemp no longer fits with LGC's investment objectives. LGC has a number of other investment opportunities that it believes will offer better short-term returns for its shareholders. The amounts invested by LGC in its due diligence review of House of Hemp were not material.

John McMullen, LGC's CEO, commented; "LGC has a number of very exciting projects that are now moving rapidly towards commercial medical cannabis production. These businesses are LGC's prime focus. We are looking forward to Little Green Pharma harvesting its first commercial crop in Australia in the next few weeks, and AAA Trichomes breaking ground at its new facility in Montreal over the coming weeks. In addition, LGC is working hard with the Global Canna Labs team in Jamaica to complete our detailed due diligence and assist its management team with its first commercial planting expected to commence next month. Italy's Evolution Bnk, which already has a cash flow, is on track to begin planting its first cannabis crops this summer. Our investments in Little Green Pharma and AAA Trichomes and our pending investments in Global Canna Labs and Evolution Bnk, in Australia, Canada, Jamaica and Italy, all have the potential for significant production of medical cannabis as each operation grows. Our CLV Frontier Brands joint venture with Creso Pharma Limited and Baltic Beer Company Ltd is on track to be in full commercial production and distribution this summer.

Mr. McMullen continued, "With respect to terminating the House of Hemp transaction, the absence of medical cannabis legislation in South Africa unfortunately means that House of Hemp's business is no longer one that suits LGC's business objectives of investing in near-term cash-flowing businesses. Not every investment LGC investigates will be concluded, and if businesses do not 100% stack-up for any reason whatsoever with respect to due diligence, budgets, timing or production potential, LGC will walk away from these opportunities to focus on better suited investment opportunities around the globe that meet our strict investment criteria."

Closing of LGC's transactions with Global Canna Labs and Evolution Bnk, respectively, is subject to the parties entering into definitive agreements, standard closing conditions, and regulatory approval, including that of the TSX Venture Exchange.

About LGC (hxxp://www.lgc-capital.com)

LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: LG). LGC's objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services.

[hottingup] 22/3/2018 09:33

This promising small-cap stock could be a millionaire maker in 2018
Paul Summers
Tue. 26/12/2017



The suggestion that a single stock could lead some investors to become millionaires next year may sound fanciful but I think this is quite possible if events work out for small-cap drug discovery and development firm ImmuPharma (LSE: IMM). Let me explain.

Blockbuster potential

Over the last three months, shares in the AIM-listed company have climbed more than 200% in value as anticipation grows over the outcome of a Phase III clinical trial for Lupuzor — its 100%-owned potential treatment for Lupus.

Approximately five million people are believed to suffer from the chronic and potentially life-threatening autoimmune disease that can be a notoriously difficult to treat. In the last 50 years, only one therapy — GlaxoSmithKline‘s Benlysta — has been approved for use, despite its questionable efficacy and serious side-effects. In 2015, the drug achieved sales of over $400m. By 2020, this figure is expected to rise to $1bn.

Positively, data from Lupozor’s Phase IIb trial indicated that ImmuPharma’s treatment — which modulates rather than blocks the immune system — was both effective and safe. Moreover, the effectiveness of Lupuzor increased even after the three-month trial’s conclusion. Investors will be hoping that the 52-week, randomised and double-blinded study currently in progress (involving patients in the US, Europe and Mauritius) yields similar results.

In its most recent update on 21 December, the company revealed that all 200 participants had now received the full 12-month dosage and that the “robust safety record” shown in earlier trials continues to be seen. According to Chairman Tim McCarthy, the company looks forward “with continued confidence” to reporting on top-line results in Q1 of next year.

In the event of a positive outcome, ImmuPharma will then seek to exploit its Fast Track designation and push for approval from the Food and Drug Administration (FDA). Once received, the company would then be free to seek out a global licensing deal for taking Lupuzor to market or — perhaps more likely — consider takeover bids by deep-pocketed pharmaceutical giants at a price befitting its blockbuster potential. Given the suggestion that it could be used in the treatment of other diseases, the price could easily be in the billions of pounds. Right now, ImmuPharma’s market cap is a little over £200m.

Tempted? If so, it’s vital to consider the flip side of this investment.

Despite the encouraging outcomes of previous trials, the possibility of the drug failing to impress still remains. Plenty of highly promising treatments have disappointed at the last hurdle, resulting in significant capital losses for investors. Unless you’re willing to embrace this level of risk, Immupharma shouldn’t even make it on to your watchlist, let alone into your portfolio.

That’s why — as a holder of its stock — only a small proportion of my capital is invested in the company. This money can be lost. I might grumble and curse but — thanks to a degree of diversification — I won’t lose my shirt.

That said, if — and it remains a sizeable ‘if‘ — Lupuzor proves effective (or at least more efficacious than Benlysta), I’m confident that ImmuPharma could generate huge wealth for investors in a very short time period.

No investment is devoid of risk but only you can decide whether this is one worth taking.

[lithological heterogeneities] 20/3/2018 11:36

Do the maths ?Did you know there are only 3 types of people in the World.Those that can count and those that can't.

[cpap man] 20/3/2018 10:18

TOM



13-Mar-2018

www.oilvoice.com/Press/14176/Valuation-of-Oil-Shale-Market-to-Hit-at-US-740070-mn-by-2022



Valuation of Oil Shale Market to Hit at US$ 7,400.70 mn by 2022
Posted by MRR Biz

13-Mar-2018

hxxps://marketresearchreports.biz/reports/1617969/...

Increasing industrial growth and population have surged the need for fossil fuels across the world. Oil shale has the potential fulfill the future energy needs of the world. Oil shale is actually a turbid rock that contains kerogen which can produce both electricity and shale oil. Processing oil shale will ensure energy preservation and also generate employment avenues thus contributing towards both economy and society. Oil shale is mainly utilized as a fuel in thermal power plants and making variety of materials such as glass, fertilizers, and carbon black among others.

The global oil shale market stood at a valuation of US$ 1,134.60 million in 2013 and is expected to reach the valuation of US$ 7,400.70 by 2022. This progress is expected to be achieved at a healthy CAGR of 27.34% from 2014 to 2022.

More Research and Development Experiments are underway for In-Situ Extraction Process

Red Leaf Resources is anticipated to progress in the market during the forecast period with the help of its hybrid EcoShale In-Capsule technology.

[yawn3] 20/3/2018 07:58

RRR..........Do the maths!

Further to the announcement of 22 January 2018, Jupiter Mines Limited ("Jupiter"), an Australian unlisted public company, has announced the completion of the AUD 51,000,000 equal access share buy back.
Acceptances were received in respect of 96.86% of shares subject to the buy back offer. Jupiter now has 1,948,340,503 shares in issue.

Red Rock has received USD 501,410.36, equivalent to approximately £357,786 at current exchange rates.



This distribution follows distributions by Jupiter to Red Rock of £537,131 on 13 March 2017 and approximately £233,606 on 16 November 2017.

No net new money is being sought through the IPO and Listing. Most institutional shareholders in Jupiter have agreed to sell a part of their holdings to ensure an adequate free float post-listing. Red Rock has agreed to sell 4,700,000 shares (20.2% of its holding in Jupiter) and to hold the remaining 18,524,914 shares in escrow for a period after listing, In the event the IPO and Listing proceed, Red Rock will receive AUD 1,880,000 before expenses and retain a 0.95% stake in the issued share capital of Jupiter, which at the Listing price will have a value of AUD 7,409,966.

[the stigologist] 19/3/2018 22:56

PYC

All this Cambridge Analytica stuff shows what can be done with simple manipulation of Big Data using machine learning/AI etc to 'win' elections

Just imagine how much good could come from manipulation of all the data gathered in historic biotech/pharmaceutical Clinical Trials if it was digitised and analysed by machine learning/AI algorithms to find 'perfect' combinations of therapies/dosing/scheduling for particular sub-populations of people with a certain disease

This is a potential Holy Grail tech solution for which Physiomics are massively well placed to drive and benefit from

[yawn3] 19/3/2018 14:51

GUN

Seeing some interest.